Bexsero® chronicle

Pathogens and Global Health

Volumn 108, Issue 7, 2014, Pages 305-311

  Vernikos, George ^a   Medini, Duccio ^b  

^a Novartis (Hellas) SACI   (Greece)

^b NOVARTIS VACCINES AND DIAGNOSTICS   (Italy)

Author keywords

4CMenB; Antigen Typing System (MATS); Bexsero; Meningococcal; Neisseria meningitidis; Serogroup B meningitis

Indexed keywords

MENINGOCOCCUS VACCINE; PROTEOLIPOSOME;

COST EFFECTIVENESS ANALYSIS; DRUG TOLERABILITY; FEVER; GENE EXPRESSION; GENE SEQUENCE; HUMAN; IMMUNIZATION; IMMUNOGENICITY; INJECTION SITE ERYTHEMA; INJECTION SITE REACTION; MENINGOCOCCOSIS; NEISSERIA MENINGITIDIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVERSE VACCINOLOGY; REVIEW; SENSITIVITY AND SPECIFICITY; VACCINATION;

EID: 84919953087     PISSN: 20477724     EISSN: 20477732     Source Type: Journal    
DOI: 10.1179/2047773214Y.0000000162     Document Type: Review

References (75)

1. Ehreth J. The global value of vaccination. Vaccine. 2003. 21(7-8). 596-600.
2. Koff WC, Burton DR, Johnson PR, Walker BD, King CR, Nabel GJ, et al. Accelerating next-generation vaccine development for global disease prevention. Science. 2013. 340(6136). 1232910.
3. Anonymous. Epidemics of meningococcal disease. African meningitis belt, 2001. Wkly Epidemiol. 2000. 76(37). 282-8.
4. Vieusseux M. Mémoire sur la maladie qui a regné a Genêve au printemps de 1805. J Med Chir Pharm. 1805. 11. 163-82.
5. Harrison OB, Claus H, Jiang Y, Bennett JS, Bratcher HB, Jolley KA, et al. Description and nomenclature of Neisseria meningitidis capsule locus. Emerg Infect Dis. 2013. 19(4). 566-73
6. Public Health Agency of Canada. Canada Commun Dis Rep (CCDR). 2007. 33. 1-15.
7. Ines Agudelo C, Sanabria OM, Ovalle MV. Serogroup Y Meningococcal disease, Colombia. Emerg Infect Dis. 2008. 14(6). 990-1.
8. Ciccone FH, Suzuki E, Pellini AC. Meningococcal disease. communitarian outbreak investigation in Grajau, in the city of Sao Paulo. BEPA. 2006. 3. 7-12.
9. Chiavetta L, Chavez E, Ruzic A, Mollerach M, Regueira M. [Surveillance of Neisseria meningitidis in Argentina, 1993-2005. distribution of serogroups, serotypes and serosubtypes isolated from invasive disease]. Rev Argent Microbiol. 39(1). 21-7. Spanish
10. Nicolas P, Norheim G, Garnotel E, Djibo S, Caugant DA. Molecular epidemiology of neisseria meningitidis isolated in the African Meningitis Belt between 1988 and 2003 shows dominance of sequence type 5 (ST-5) and ST-11 complexes. J Clin Microbiol. 2005. 43(10). 5129-35.
11. Coulson GB, von Gottberg A, du Plessis M, Smith AM, de Gouveia L, Klugman KP, et al. Meningococcal disease in South Africa, 1999-2002. Emerg Infect Dis. 2007. 13(2). 273-81
12. Chiou CS, Liao JC, Liao TL, Li CC, Chou CY, Chang HL, et al. Molecular epidemiology and emergence of worldwide epidemic clones of Neisseria meningitidis in Taiwan. BMC Infect Dis. 2006. 6. 25.
13. Takahashi H, Kuroki T, Watanabe Y, Tanaka H, Inouye H, Yamai S, et al. Characterization of Neisseria meningitides isolates collected from 1974 to 2003 in Japan by multilocus sequence typing. J Med Microbiol. 2004. 53(Pt 7). 657-62.
14. Australian Meningococcal Surveillance Programme. CDI. 2007. 31. 185-93.
15. Black S, Pizza M, Nissum M, Rappuoli R. Toward a meningitis-free world. Sci Transl Med. 2012. 4(123). 123-125
16. Stephens DS. Conquering the meningococcus. FEMS Microbiol Rev. 2007. 31(1). 3-14.
17. Atkinson W, Wolfe S, Hamborsky J, editors. Centers for Disease Control and Prevention meningococcal disease. The pink book. epidemiology and prevention of vaccine-preventable diseases. 12th ed. Washington, DC. Public Health Foundation. 2011.
18. Thompson MJ, Ninis N, Perera R, Mayon-White R, Phillips C, Bailey L, et al. Clinical recognition of meningococcal disease in children and adolescents. Lancet. 2006. 367(9508). 397-403.
19. Rosenstein NE, Perkins BA, Stephens DS, Popovic T, Hughes JM. Meningococcal disease. N Engl J Med. 2001. 344(18). 1378-88
20. European Centre for Disease Prevention and Control. Surveillance of invasive bacterial diseases in Europe 2008/ 2009. Stockholm. ECDC. 2011.
21. World Health Organization. Meningococcal meningitis factsheet. Geneva. WHO. 2010.
22. Trotter CL, Gay NJ, Edmunds WJ. The natural history of meningococcal carriage and disease. Epidemiol Infect. 2006. 134(3). 556-66.
23. Virji M. Meningococcal disease. epidemiology and pathogenesis. Trends Microbiol. 1996. 4(12). 466-9. discussion 469-70
24. Coutinho A, Moller G. Mitogenic properties of the thymusindependent antigen pneumococcal polysaccharide S3. Eur J Immunol. 1973. 3(10). 608-13.
25. Swain CL, Martin DR. Survival of meningococci outside of the host. implications for acquisition. Epidemiol Infect. 2007. 135(2). 315-20.
26. Azurmendi HF, Vionnet J, Wrightson L, Trinh LB, Shiloach J, Freedberg DI. Extracellular structure of polysialic acid explored by on cell solution NMR. Proc Natl Acad Sci USA. 2007. 104(28). 11557-61.
27. Finne J, Leinonen M, Makela PH. Antigenic similarities between brain components and bacteria causing meningitis. Implications for vaccine development and pathogenesis. Lancet. 1983. 2(8346). 355-7.
28. Finne J, Bitter-Suermann D, Goridis C, Finne U. An IgG monoclonal antibody to group B meningococci cross-reacts with developmentally regulated polysialic acid units of glycoproteins in neural and extraneural tissues. J Immunol. 1987. 138(12). 4402-7.
29. Isomura R, Kitajima K, Sato C. Structural and functional impairments of polysialic acid by a mutated polysialyltransferase found in schizophrenia. J Biol Chem. 2011. 286(24). 21535-45.
30. Budroni S, Siena E, Dunning Hotopp JC, Seib KL, Serruto D, Nofroni C, et al. Neisseria meningitidis is structured in clades associated with restriction modification systems that modulate homologous recombination. Proc Natl Acad Sci USA. 2011. 108(11). 4494-9.
31. Kuehn MJ, Kesty NC. Bacterial outer membrane vesicles and the host-pathogen interaction. Genes Dev. 2005. 19(22). 2645-55
32. Mayrand D, Grenier D. Biological activities of outer membrane vesicles. Can J Microbiol. 1989. 35(6). 607-13.
33. Zhou L, Srisatjaluk R, Justus DE, Doyle RJ. On the origin of membrane vesicles in Gram-negative bacteria. FEMS Microbiol Lett. 1998. 163(2). 223-8.
34. Pettit RK, Judd RC. The interaction of naturally elaborated blebs from serum-susceptible and serum-resistant strains of Neisseria gonorrhoeae with normal human serum. Mol Microbiol. 1992. 6(6). 729-34.
35. Craven DE, Peppler MS, Frasch CE, Mocca LF, McGrath PP, Washington G. Adherence of isolates of Neisseria meningitides from patients and carriers to human buccal epithelial cells. J Infect Dis. 1980. 142(4). 556-68.
36. Stephens DS, Edwards KM, Morris F, McGee ZA. Pili and outer membrane appendages on Neisseria meningitidis in the cerebrospinal fluid of an infant. J Infect Dis. 1982. 146(4). 568
37. Namork E, Brandtzaeg P. Fatal meningococcal septicaemia with ‘‘blebbing’’ meningococcus. Lancet. 2002. 360(9347). 1741
38. Zollinger WD, Boslego J, Frøholm LO, Ray JS, Moran EE, Brandt BL. Human bactericidal antibody response to meningococcal outer membrane protein vaccines. Antonie van Leeuwenhoek. 1987. 53(6). 403-11.
39. Zollinger WD, Mandrell RE, Altieri P, Berman S, Lowenthal J, Artenstein MS. Safety and immunogenicity of a Neisseria meningitidis type 2 protein vaccine in animals and humans. J Infect Dis. 1978. 137(6). 728-39.
40. Helting TB, Guthohrlein G, Blackkolb F, Ronneberger H. Serotype determinant protein of Neisseria meningitidis. Large scale preparation by direct detergent treatment of the bacterial cells. Acta Pathol Microbiol Scand Sect C Immunol. 1981. 89(2). 69-78.
41. Frasch CE, Robbins JD. Protection against group B meningococcal disease. III. Immunogenicity of serotype 2 vaccines and specificity of protection in a guinea pig model. J Exp Med. 1978. 147(3). 629-44.
42. Arnold R, Galloway Y, McNicholas A, O’Hallahan J. Effectiveness of a vaccination programme for an epidemic of meningococcal B in New Zealand. Vaccine. 2011. 29(40). 7100-6
43. Sierra GV, Campa HC, Varcacel NM, Garcia IL, Izquierdo PL, Sotolongo PF, et al. Vaccine against group B Neisseria meningitidis. protection trial and mass vaccination results in Cuba. NIPH Ann. 1991. 14(2). 195-207. discussion 208-10.
44. Rosenqvist E, Høiby EA, Wedege E, Bryn K, Kolberg J, Klem A, et al. Human antibody responses to meningococcal outer membrane antigens after three doses of the Norwegian group B meningococcal vaccine. Infect Immun. 1995. 63(12). 4642-52
45. Sotolongo F, Campa C, Casanueva V, Fajardo EM, Cuevas IE, González N. Cuban meningococcal BC vaccine. experiences & contributions from 20 years of application. MEDICC Rev. 2007. 9(1). 16-22.
46. Holst J, Nokleby H, Bettinger JA. Considerations for controlling invasive meningococcal disease in high income countries. Vaccine. 2012. 30(Suppl 2). B57-62.
47. Holst J, Martin D, Arnold R, Huergo CC, Oster P, O’Hallahan J, et al. Properties and clinical performance of vaccines containing outer membrane vesicles from Neisseria meningitidis. Vaccine. 2009. 27(Suppl 2). B3-12.
48. van der Voort ER, van Dijken H, Kuipers B, van der Biezen J, van der Ley P, Meylis J, et al. Human Band T-cell responses after immunization with a hexavalent PorA meningococcal outer membrane vesicle vaccine. Infect Immun. 1997. 65(12). 5184-90.
49. Willis NJ. Edward Jenner and the eradication of smallpox. Scott Med J. 1997. 42(4). 118-21.
50. Rappuoli R, Mandl CW, Black S, de Gregorio E. Vaccines for the twenty-first century society. Nat Rev Immunol. 2011. 11(12). 865-72.
51. Fleischmann RD, Adams MD, White O, Clayton RA, Kirkness EF, Kerlavage AR, et al. Whole-genome random sequencing and assembly of Haemophilus influenzae Rd. Science. 1995. 269(5223). 496-512.
52. Rappuoli R. Reverse vaccinology. Curr Opin Microbiol. 2000. 3(5). 445-50.
53. Maione D, Margarit I, Rinaudo CD, Masignani V, Mora M, Scarselli M, et al. Identification of a universal Group B streptococcus vaccine by multiple genome screen. Science. 2005. 309(5731). 148-50.
54. Pizza M, Scarlato V, Masignani V, Giuliani MM, Aricò B, Comanducci M, et al. Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing. Science. 2000. 287(5459). 1816-20.
55. Gorringe AR, Pajon R. Bexsero. a multicomponent vaccine for prevention of meningococcal disease. Hum Vaccines Immunother. 2012. 8(2). 174-83.
56. Bambini S, Piet J, Muzzi A, Keijzers W, Comandi S, De Tora L, et al. An analysis of the sequence variability of meningococcal fHbp, NadA and NHBA over a 50-year period in the Netherlands. PLoS One. 2013. 8(5). e65043.
57. Bexsero (summary of product characteristics). Siena. Novartis Vaccines and Diagnostics S.r.l.. 2013.
58. Snape MD, Dawson T, Oster P, Evans A, John TM, OheneKena B, et al. Immunogenicity of two investigational serogroup B meningococcal vaccines in the first year of life. a randomized comparative trial. Pediatr Infect Dis J. 2010. 29(11). e71-9.
59. Gossger N, Snape MD, Yu LM, Finn A, Bona G, Esposito S, et al. Immunogenicity and tolerability of recombinant serogroup B meningococcal vaccine administered with or without routine infant vaccinations according to different immunization schedules. a randomized controlled trial. JAMA. 2012. 307(6). 573-82.
60. Vesikari T, Esposito S, Prymula R, Ypma E, Kohl I, Toneatto D, et al. Immunogenicity and safety of an investigational multicomponent, recombinant, meningococcal serogroup B vaccine (4CMenB) administered concomitantly with routine infant and child vaccinations. results of two randomised trials. Lancet. 2013. 381(9869). 825-35.
61. Vogel U, Taha MK, Vazquez JA, Findlow J, Claus H, Stefanelli P, et al. Predicted strain coverage of a meningococcal multicomponent vaccine (4CMenB) in Europe. a qualitative and quantitative assessment. Lancet Infect Dis. 2013. 13(5). 416-25
62. Data on file. Emeryville, CA. Novartis Vaccines and Diagnostics
63. Donnelly J, Medini D, Boccadifuoco G, Biolchi A, Ward J, Frasch C, et al. Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of protein-based vaccines. Proc Natl Acad Sci USA. 2010. 107(45). 19490-5.
64. Frosi G, Biolchi A, Lo Sapio M, Rigat F, Gilchrist S, Lucidarme J, et al. Bactericidal antibody against a representative epidemiological meningococcal serogroup B panel confirms that MATS underestimates 4CMenB vaccine strain coverage. Vaccine. 2013. 31(43). 4968-74.
65. EMA. Authorization Details for Bexsero. Available from. http.//www.ema.europa.eu/ema/index.jsp?curl5pages/medicines/human/medicines/002333/human_med_001614.jsp& mid5WC0b01ac058001d124
66. Health Canada. Bexsero. Available from. http.//www.hc-sc.gc.ca/dhp-mps/prodpharma/sbd-smd/drug-med/sbd_smd_2014_bexsero_147275-eng.php
67. Australian Government. Department of Health. Therapeutic Goods Administration. Available from.
68. http.//www.tga.gov.au/pdf/auspar/auspar-meningococcal-131031.pdf
69. Centers for Disease Control and Prevention. Princeton University meningococcal disease outbreak. December 2013. Available from. http. //www.cdc.gov/meningococcal/outbreaks/ princeton.html
70. Centers for Disease Control and Prevention. University of California, Santa Barbara meningococcal disease outbreak. January 2014. Available from. http. //www.cdc.gov/meningo-occal/outbreaks/ucsb.html
71. US Food and Drug Administration. Frequently asked questions. breakthrough therapies. Available from. http.//www.fda.gov/regulatoryinformation/legislation/federalfooddrugand-osmeticactfdcact/significantamendmentstothefdcact/fdasia/ ucm341027.htm
72. Wise J. Meningitis B vaccine to be introduced in UK after U turn on its cost effectiveness. BMJ. 2014. 348. g2327
73. Madhavan G, Sangha K, Phelps C, Fryback D, Rappuoli R, Martinez RM, King L, editors. Ranking vaccines. a prioritization software tool. phase II. prototype of a decision-support system. Washington, DC. National Academy of Sciences. 2013.
74. Hinman AR. Global progress in infectious disease control. Vaccine. 1998. 16(11-12). 1116-21.
75. Hsu HE, Shutt KA, Moore MR, Beall BW, Bennett NM, Craig AS, et al. Effect of pneumococcal conjugate vaccine on pneumococcal meningitis. N Engl J Med. 2009. 360(3). 244-56.